NACC2

Across TCGA pan-cancer cohorts, NACC2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NACC2 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher NACC2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NACC2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SARC, DLBC, and PRAD are the cancer types where NACC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
DLBC	OS	Median	All	0.613	0.946	.013	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	1.000	0.719	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NACC2–SARC (DFS)

Open the SARC breakdown →